Bemarituzumab FIGHTs Gastric/GEJ Cancers, Improving Survival Bemarituzumab FIGHTs Gastric/GEJ Cancers, Improving Survival
Adding bemarituzumab to chemotherapy as first-line treatment for advanced gastric and gastroesophageal junction (GEJ) cancers improved survival over chemotherapy alone in the phase 2 FIGHT trial.Medscape Medical News
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Hematology